Cervarix, Prevenar and Januvia among new Japanese approvals
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's Cervarix has become the first cervical cancer vaccine to be approved in Japan, following a formal regulatory clearance from the country's ministry of health, labour and welfare.